
Tranexamic Acid and Trauma

KARL SPORER, ALAMEDA COUNTY EMS AGENCY



- ▶ Tranexamic Acid
 - ► Inhibits Fibrinolysis
 - ► CRASH 2 Trial demonstrated 1.5 to 2.4% mortality benefit in severe trauma patients
 - ▶ 20,000 patients were randomized
 - Secondary studies demonstrated that earlier use improved survival

- Multi center, prospective cohort with a retrospective cohort
- ► Three California Counties implemented TXA in 362 severe trauma patients
 - ► San Bernardino
 - ▶ Riverside
 - Alameda
 - ▶ 362 Propensity Score Matching Cases

- Primary Outcomes
 - Mortality at 24 hours, 48 hours, 28 days
 - ► Total Blood Products
 - ► Hospital and ICU length of stay

- ► Mortality at 28 Days
 - ► TXA 3.6%
 - Control 8.3%
- ► Severely injured (ISS >15), 28 day mortality
 - ► TXA 6%
 - ► Control 14.5%
- ► Significant Reduction in Blood Transfusion requirements

- Real World Implementation in three counties
- Hospital infusion is commonly not performed
- Average to poor EMS compliance
- Morality and Blood Transfusion improvements despite these issues

TXA in TBI

(2 gm IV bolus appears be beneficial in ICH)

Craig Manifold, DO

Sharing information presented at the 2018 Military Health System Research Symposium

A Two Gram Bolus of Tranexamic Acid Improves Survival After Traumatic Brain Injury in Patients with Intracranial Hemorrhage

Martin A. Schreiber MD FACS
COL, MC, USAR
Professor of Surgery
Oregon Health & Science University






- 3-arm randomized trial (1:1:1)
- Multi-center, multi-national
- Double-blinded
- Key coded kits placed on rigs and replaced at trauma center when used







To determine the effects of two dosing strategies of TXA on outcome following moderate to severe TBI





- No difference in favorable neurologic outcome at 6 months (primary)
- No difference in 28 day survival
- No difference in morbidity

Comparing patients who received 2 dosing strategies of TXA to those who did not receive TXA





Inclusion Criteria

- Blunt or penetrating TBI
- GCS = 3 12
- Prehospital SBP ≥ 90 mmHg
- Age ≥15 y/o, or ≥50 kg, if age unknown
- IV placed
- Planned transport to participating hospital


Exclusion Criteria

- GCS = 3 with no reactive pupil
- > 2 hours from time of injury or time unknown
- Any prehospital CPR
- Seizures, MI, stroke, dialysis
- Known or suspected prisoners
- Known/suspected pregnancy
- Drowning or hanging
- Burns >20% TBSA
- TXA or pro-coagulant drug
- Opt out











Randomization Groups

- 2 gram PH bolus, 8 hour IH placebo infusion
 - BO
- 1 gram PH bolus, 8 hour IH 1 gram infusion
 - BM
- Placebo PH bolus, 8 hour IH placebo infusion
 - PB





- Enrollment from May 2015 Mar 2017
- 967 patients randomized and received drug
 - 346* BO
 - 312 BM
 - 309 PB
 - * 1 excluded from analysis because enrolled while in police custody






_					OR for 28-Day Mortality (95% CI)		
		28-Day Mortality, n (%)			Pairwise Comparisons		
		PB	BM	ВО	BM v. PB	BO v. PB	BO v. BM
٨	/lortality						
	All patients	53 (17)	53 (17)	41 (12)	1.01 (0.66, 1.55)	0.66 (0.42, 1.03)	0.65 (0.42, 1.02)
	ICH on initial CT	51 (28)	51 (28)	36 (18)	1.03 (0.56, 1.88)	0.47 (0.25, 0.89)	0.46 (0.25, 0.86)






ICH patients through 30 days



ICH patients through 72 hours







	PB	BM	ВО
	N = 309	N = 312	N = 345
Key adverse events, n (%)			
Seizure	7 (2)	5 (2)	17 (5)
Any thromboembolic event	30 (10)	13 (4)	32 (9)
MI	1 (0)	3 (1)	2 (1)
PE	5 (2)	3 (1)	6 (2)
Thrombotic stroke	10 (3)	3 (1)	13 (4)
DVT	9 (3)	3 (1)	9 (3)
Other	10 (3)	1 (0)	13 (4)






Conclusions

- Prehospital TXA use is feasible
- Does not result in favorable GOSE at 6 months
- Does not affect TEG on admit
- 2 grams prehospital TXA results in improved 28 day survival in patients with ICH
- 1st therapeutic with evidence for benefit in acute TBI
- What about hemorrhagic shock?
















- NIH) National Heart, Lung and Blood Institute
- Institute of Circulatory and Respiratory Health of the Canadian Institute of Health Research
- Defence Research and Development Canada
- Heart and Stroke Foundation of Canada
- American Heart Association





- · Martin A. Schreiber MD
- Susan E. Rowell MD
- · Eric N. Meier MS
- Barbara McKnight, PhD
- Susanne May, PhD
- Delores Kannas, RN, MS, MHA
- Kellie Sheehan, BSN
- Jun Hwang, MS
- Patrick L. Bosarge, MD
- · Carolyn Williams, RN
- · Rob Schlamp, CCP
- · John Tallon, MD
- Jim Christenson, MD
- Jay Johannigman, MD
- Jason McMullan, MD
- · Ahamed H. Idris, MD

- Rajesh R. Gandhi, MD, PhD
- Mark Gamber, DO
- · Neal J. Richmond, MD
- · William Witham, MD
- Robert Simonson, DO
- · John S. Garrett, MD
- Brian Tibbs, MD
- Bryan A. Cotton, MD
- · Laura E. Vincent, RN
- Martin D. Zielinski, MD
- · Michael Ferrara
- M. Riccardo Colella, DO, MPH
- Tom P. Aufderheide, MD
- Audrey Hendrickson, MPH, CCRP
- · Lauren Klein, MD, MS
- · George Sopko, MD

- Myron L. Weisfeldt, MD
- · Ralph J. Frascone, MD
- · David J. Dries, MD
- · Eileen M. Bulger, MD
- Bryce R. H. Robinson, MD
- · Patricia Klotz, RN
- Laurie J. Morrison, MD
- Jeannie Callum, MD
- Sandro Rizoli, MD
- The ROC Investigators


























Collaboration



TRANSFORMING TRAUMA CARE






















Deploy

Save Lives

Woman survives traumatic crash thanks to new resource on SAFD EMS units

By Sarah Acosta - Reporter, Joe Herrera - Photojournalist

Posted: 8:40 PM, February 19, 2019 Updated: 3:29 AM, February 20, 2019







Questions?

Contact

- C. J. Winckler MD, LP
- winckler@uthscsa.edu
- 512-750-1772



